| A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease AD Roses, MW Lutz, H Amrine-Madsen, AM Saunders, DG Crenshaw, ... The pharmacogenomics journal 10 (5), 375, 2010 | 453 | 2010 |
| The mitotic peptidyl‐prolyl isomerase, Pin1, interacts with Cdc25 and Plx1 DG Crenshaw, J Yang, AR Means, S Kornbluth The EMBO Journal 17 (5), 1315-1327, 1998 | 274 | 1998 |
| Genetic variation at a single locus and age of onset for Alzheimer's disease MW Lutz, DG Crenshaw, AM Saunders, AD Roses Alzheimer's & Dementia 6 (2), 125-131, 2010 | 118 | 2010 |
| Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. II. In vivo studies. DG Crenshaw, TS Hsieh Journal of Biological Chemistry 268 (28), 21335-21343, 1993 | 103 | 1993 |
| The cis-regulatory effect of an Alzheimer’s disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes C Linnertz, L Anderson, W Gottschalk, D Crenshaw, MW Lutz, J Allen, ... Alzheimer's & Dementia 10 (5), 541-551, 2014 | 92 | 2014 |
| Characterization of the poly-T variant in the TOMM40 gene in diverse populations C Linnertz, AM Saunders, MW Lutz, DM Crenshaw, I Grossman, DK Burns, ... PloS one 7 (2), e30994, 2012 | 79 | 2012 |
| Using genetics to enable studies on the prevention of Alzheimer's disease DG Crenshaw, WK Gottschalk, MW Lutz, I Grossman, AM Saunders, ... Clinical Pharmacology & Therapeutics 93 (2), 177-185, 2013 | 76 | 2013 |
| TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial AD Roses, MW Lutz, DG Crenshaw, I Grossman, AM Saunders, ... Alzheimer's & Dementia 9 (2), 132-136, 2013 | 72 | 2013 |
| New applications of disease genetics and pharmacogenetics to drug development AD Roses, AM Saunders, MW Lutz, N Zhang, AR Hariri, KE Asin, ... Current opinion in pharmacology 14, 81-89, 2014 | 67 | 2014 |
| Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. II. In vivo studies. DG Crenshaw, TS Hsieh Journal of Biological Chemistry 268 (28), 21335-21343, 1993 | 67 | 1993 |
| Alzheimer’s disease: diagnostics, prognostics and the road to prevention I Grossman, MW Lutz, DG Crenshaw, AM Saunders, DK Burns, AD Roses EPMA Journal 1 (2), 293-303, 2010 | 51 | 2010 |
| New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics MW Lutz, D Crenshaw, KA Welsh-Bohmer, DK Burns, AD Roses Current neurology and neuroscience reports 16 (5), 48, 2016 | 35 | 2016 |
| Catalytically active hybrids formed in vitro between large and small subunits of different procaryotic ribulose bisphosphate carboxylases TJ Andrews, DM Greenwood, D Yellowlees Archives of biochemistry and biophysics 234 (1), 313-317, 1984 | 33 | 1984 |
| Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain DG Crenshaw, K Asin, WK Gottschalk, Z Liang, N Zhang, AD Roses PloS one 10 (2), e0117973, 2015 | 25 | 2015 |
| Pipeline pharmacogenetics: a novel approach to integrating pharmacogenetics into drug development PA Akkari, TW Swanson, DG Crenshaw, I Grossman, S Sundseth, ... Current pharmaceutical design 15 (32), 3754-3763, 2009 | 11 | 2009 |
| P4‐269: A pharmacogenetic‐supported clinical trial to delay onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) AD Roses, K Welsh‐Bohmer, D Burns, C Chiang, DG Crenshaw, MW Lutz, ... Alzheimer's & Dementia 8 (4S_Part_20), S753-S753, 2012 | 10 | 2012 |
| P4–065: A pharmacogenetics‐supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease A Roses, K Welsh‐Bohmer, D Burns, C Chiang, DG Crenshaw, MW Lutz, ... Alzheimer's & Dementia 9, P727-P727, 2013 | 8 | 2013 |
| The importance of being connected MW Lutz, DG Crenshaw, AM Saunders, AD Roses Journal of Alzheimer's Disease 24 (2), 247-251, 2011 | 8 | 2011 |
| Traversing the cell cycle: the calcium/calmodulin connection. AR Means, CR Kahl, DG Crenshaw, JS Dayton Calcium as a cellular regulator, E. Carafoli and C. Klee (ed.), 512-528, 1999 | 8 | 1999 |
| A PHARMACOGENETICS-SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE USING LOW-DOSE PIOGLITAZONE: AN UPDATE ON THE TOMORROW STUDY K Budur, K Welsh-Bohmer, D Burns, C Chiang, J O'Neil, G Runyan, ... Alzheimer's & Dementia: The Journal of the Alzheimer's Association 10 (4 …, 2014 | 6 | 2014 |
